Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort
Tóm tắt
Từ khóa
Tài liệu tham khảo
D'Amico, 2018, Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study, Eur J Neurol., 25, 1425, 10.1111/ene.13745
Confavreux, 2014, The clinical course of multiple sclerosis, Handb Clin Neurol., 122, 343, 10.1016/B978-0-444-52001-2.00014-5
Battaglia, 2017, Estimated prevalence of multiple sclerosis in Italy in 2015, Neurol Sci., 38, 473, 10.1007/s10072-016-2801-9
Nicoletti, 2011, Increasing frequency of multiple sclerosis in Catania, Sicily: a 30-year survey, Mult Scler., 17, 273, 10.1177/1352458510386995
Cools, 2007, Regulatory T cells and human disease, Clin Dev Immunol., 2007, 89195, 10.1155/2007/89195
Shevach, 2000, Regulatory T cells in autoimmmunity, Annu Rev Immunol., 18, 423, 10.1146/annurev.immunol.18.1.423
Dranoff, 2005, The therapeutic implications of intratumoral regulatory T cells, Clin Cancer Res., 11, 8226, 10.1158/1078-0432.CCR-05-2035
Oleinika, 2013, Suppression, subversion and escape: the role of regulatory T cells in cancer progression, Clin Exp Immunol., 171, 36, 10.1111/j.1365-2249.2012.04657.x
Hofer, 2010, Cancer risk among patients with multiple sclerosis and their parents, Neurology., 74, 614, 10.1212/WNL.0b013e3181c777b7
Midgard, 1996, Multiple sclerosis and cancer in Norway, A retrospective cohort study Acta Neurol Scand., 93, 411, 10.1111/j.1600-0404.1996.tb00019.x
Vesely, 2011, Natural innate and adaptive immunity to cancer, Annu Rev Immunol., 29, 235, 10.1146/annurev-immunol-031210-101324
Etemadifar, 2017, Cancer risk among patients with multiple sclerosis: a cohort study in Isfahan, Iran, Caspian J Intern Med., 8, 172, 10.22088/cjim.8.3.172
Moller, 1991, Cancer incidence following hospitalization for multiple sclerosis in Denmark, Acta Neurol Scand., 84, 214, 10.1111/j.1600-0404.1991.tb04941.x
Kyritsis, 2016, Cancer specific risk in multiple sclerosis patients, Crit Rev Oncol Hematol., 98, 29, 10.1016/j.critrevonc.2015.10.002
Vidal-Jordana, 2018, New advances in disease-modifying therapies for relapsing and progressive forms of multiple sclerosis, Neurol Clin., 36, 173, 10.1016/j.ncl.2017.08.011
English, 2015, New FDA-approved disease-modifying therapies for multiple sclerosis, Clin Ther., 37, 691, 10.1016/j.clinthera.2015.03.001
Lebrun, 2018, Cancer risk in patients with multiple sclerosis: potential impact of disease-modifying drugs, CNS Drugs., 32, 939, 10.1007/s40263-018-0564-y
Marrie, 2015, A systematic review of the incidence and prevalence of cancer in multiple sclerosis, Mult Scler., 21, 294, 10.1177/1352458514564489
Lebrun, 2007, [CARIMS (Cancer Risk In Multiple Sclerosis) project: impact of long-term treatment], Rev Neurol., 163, 38, 10.1016/S0035-3787(07)90353-7
Kingwell, 2014, Assessment of cancer risk with beta-interferon treatment for multiple sclerosis, J Neurol Neurosurg Psychiatry., 85, 1096, 10.1136/jnnp-2013-307238
Gaindh, 2016, Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk, J Neurol Sci., 370, 13, 10.1016/j.jns.2016.09.005
Ragonese, 2017, Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study, BMC Neurol., 17, 155, 10.1186/s12883-017-0932-0
Nielsen, 2006, Cancer risk among patients with multiple sclerosis: a population-based register study, Int J Cancer., 118, 979, 10.1002/ijc.21437
Kingwell, 2012, Cancer risk in multiple sclerosis: findings from British Columbia, Canada, Brain., 135, 2973, 10.1093/brain/aws148
Polman, 2011, Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria, Ann Neurol., 69, 292, 10.1002/ana.22366
Moisset, 2017, Decreased prevalence of cancer in patients with multiple sclerosis: a case-control study, PLoS ONE., 12, e0188120, 10.1371/journal.pone.0188120
Fois, 2010, Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies, J Neurol Neurosurg Psychiatry., 81, 215, 10.1136/jnnp.2009.175463
Norgaard, 2018, Multiple sclerosis and cancer incidence: a Danish nationwide cohort study, Mult Scler Relat Disord., 28, 81, 10.1016/j.msard.2018.12.014
Campisi, 2013, Aging, cellular senescence, and cancer, Annu Rev Physiol., 75, 685, 10.1146/annurev-physiol-030212-183653
Key, 2003, Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women, J Natl Cancer Inst., 95, 1218, 10.1093/jnci/djg022
Dorak, 2012, Gender differences in cancer susceptibility: an inadequately addressed issue, Front Genet., 3, 268, 10.3389/fgene.2012.00268
Catala-Lopez, 2014, Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta-analysis of cancer incidence in 577,013 participants of 50 observational studies, Psychother Psychosom., 83, 89, 10.1159/000356498
Auricchio, 2017, Drugs approved for the treatment of multiple sclerosis: review of their safety profile, Expert Opin Drug Saf., 16, 1359, 10.1080/14740338.2017.1388371
Nuyen, 2006, Comorbidity was associated with neurologic and psychiatric diseases: a general practice-based controlled study, J Clin Epidemiol., 59, 1274, 10.1016/j.jclinepi.2006.01.005
Sun, 2014, Increased breast cancer risk for patients with multiple sclerosis: a nationwide population-based cohort study, Eur J Neurol., 21, 238, 10.1111/ene.12267
Pellegriti, 2009, Papillary thyroid cancer incidence in the volcanic area of Sicily, J Natl Cancer Inst., 101, 1575, 10.1093/jnci/djp354
Malandrino, 2016, Increased thyroid cancer incidence in a basaltic volcanic area is associated with non-anthropogenic pollution and biocontamination, Endocrine., 53, 471, 10.1007/s12020-015-0761-0
Niederwieser, 2003, Prevalence of autoimmune thyroiditis and non-immune thyroid disease in multiple sclerosis, J Neurol., 250, 672, 10.1007/s00415-003-1053-9
Coldman, 2013, Incidence of breast cancer and estimates of overdiagnosis after the initiation of a population-based mammography screening program, CMAJ., 185, E492, 10.1503/cmaj.121791
Lebrun, 2008, Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis, Mult Scler., 14, 399, 10.1177/1352458507083625
Di Patre, 2003, “Tumor-mimicking” multiple sclerosis, Clin Neuropathol., 22, 235
Lebrun, 2011, Cancer and multiple sclerosis in the era of disease-modifying treatments, J Neurol., 258, 1304, 10.1007/s00415-011-5929-9
Handel, 2010, Multiple sclerosis and risk of cancer: a meta-analysis, J Neurol Neurosurg Psychiatry., 81, 1413, 10.1136/jnnp.2009.195776
Haussleiter, 2009, Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment, Ther Adv Neurol Disord., 2, 13, 10.1177/1756285608100325
Bsteh, 2016, Long term clinical prognostic factors in relapsing-remitting multiple sclerosis: insights from a 10-year observational study, PLoS ONE., 11, e0158978, 10.1371/journal.pone.0158978
Thormann, 2017, Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality, Neurology., 89, 1668, 10.1212/WNL.0000000000004508
Awad, 2010, Multiple sclerosis in the elderly patient, Drugs Aging., 27, 283, 10.2165/11532120-000000000-00000